Modality
Fusion Protein
MOA
Anti-Tau
Target
HER2
Pathway
STING
CKD
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
~Jul 2022
→ ~Oct 2023
Phase 2
~Jan 2024
→ ~Apr 2025
Phase 3
Jul 2025
→ Jun 2031
Phase 3Current
NCT05788434
1,739 pts·CKD
2025-07→2031-06·Completed
1,739 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-025.2y awayPh3 Readout· CKD
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P3
Complet…
Catalysts
Ph3 Readout
2031-06-02 · 5.2y away
CKD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05788434 | Phase 3 | CKD | Completed | 1739 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| Voxamavacamten | Corcept | Approved | BET |